Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30952112 | 1.00 | PRCP (0.52) | PRCPSLC22A1ALDH1A1NPSR1MAPT | |
| SCHEMBL14933933 | 1.00 | PRCP (0.52) | PRCPSLC22A1ALDH1A1NPSR1MAPT | |
| SCHEMBL3847930 | 0.89 | PRCP (0.45) | PRCPSLC22A1ALDH1A1NPSR1MAPT | |
| SCHEMBL14934054 | 0.86 | PRCP (0.50) | PRCPSLC22A1ALDH1A1OPRM1SMN1; SMN2 | |
| SCHEMBL14934071 | 0.86 | PRCP (0.50) | PRCPSLC22A1ALDH1A1OPRM1SMN1; SMN2 | |
| SCHEMBL19025988 | 0.84 | RAB9A (0.39) | PRCPSLC22A1ALDH1A1NPSR1MAPT | |
| SCHEMBL19026595 | 0.84 | RAB9A (0.39) | PRCPSLC22A1ALDH1A1NPSR1MAPT | |
| SCHEMBL19025986 | 0.84 | RAB9A (0.39) | PRCPSLC22A1ALDH1A1NPSR1MAPT | |
| SCHEMBL16017694 | 0.82 | PRCP (0.49) | PRCPSLC22A1ALDH1A1MAPTOPRM1 | |
| SCHEMBL25321589 | 0.81 | OPRM1 (0.47) | KMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112789276-A | Analgesic compounds, their preparation and their pharmaceutical use | 上海海雁医药科技有限公司 | 2021-05-11 | — | — | CN | disclosed |
| WO-2021027304-A1 | ANALGESIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2021-02-18 | — | — | WO | disclosed |
| WO-2021027304-A1 | ANALGESIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-10597378-B2 | Tetrahydroisoquinolines for use as MOR/NOP dual agonists | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-24 | — | — | US | disclosed |
| US-10597378-B2 | Tetrahydroisoquinolines for use as MOR/NOP dual agonists | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-24 | — | — | US | disclosed |
| US-20190077786-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2019-03-14 | — | — | US | disclosed |
| US-20190077786-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2019-03-14 | — | — | US | disclosed |
| US-10106502-B2 | Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-31 | — | — | US | disclosed |
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-31 | — | — | US | disclosed |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | THE BROAD INSTITUTE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | THE BROAD INSTITUTE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013067036-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067036-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597378-B2 | Tetrahydroisoquinolines for use as MOR/NOP dual agonists | OPRL1, OPRM1, OPRK1 | PRCP 2247/4885SLC22A1 2574/4885ALDH1A1 1359/4885 |
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | KEAP1, NFE2L2, HMOX1 | PRCP 2778/4885SLC22A1 2616/4885ALDH1A1 1021/4885 |
| US-10106502-B2 | Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators | KEAP1, NFE2L2, HMOX1 | PRCP 2778/4885SLC22A1 2616/4885ALDH1A1 1021/4885 |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | CD4, CD74, HAVCR2 | PRCP 348/4885SLC22A1 4555/4885ALDH1A1 4880/4885 |
| US-20190077786-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | OPRM1, OPRL1, OPRK1 | PRCP 1104/4885SLC22A1 1405/4885ALDH1A1 347/4885 |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | KEAP1, NFE2L2, HMOX1 | PRCP 2778/4885SLC22A1 2616/4885ALDH1A1 1021/4885 |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | CD4, CD74, HAVCR2 | PRCP 348/4885SLC22A1 4555/4885ALDH1A1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.